According to Ypsomed's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 62.0871. At the end of 2024 the company had a P/E ratio of 63.1.
Year | P/E ratio | Change |
---|---|---|
2024 | 63.1 | 22.41% |
2023 | 51.6 | -44.67% |
2022 | 93.2 | -74.76% |
2021 | 369 | 155.76% |
2020 | 144 | 373.41% |
2019 | 30.5 | -19.89% |
2018 | 38.1 | -35.08% |
2017 | 58.7 | 12.39% |
2016 | 52.2 | -19.52% |
2015 | 64.8 | -9.98% |
2014 | 72.0 | -83.91% |
2013 | 448 | 434.96% |
2012 | 83.7 | -38.76% |
2011 | 137 | 33.67% |
2010 | 102 | 146.3% |
2009 | 41.5 | -5.04% |
2008 | 43.7 | -92.61% |
2007 | 591 | 813.57% |
2006 | 64.7 | 35.01% |
2005 | 47.9 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.